North East and North Cumbria
ICS Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Recent Updates - Updated items
All Formulary Amendments
Records 1 to 21 of 21
Details
UPD
sitematrix Changed from 0 to
12/10/2023 11:12:16
(DavidS )
UPD
FurtherInformation Changed from
Approved for the treatment of cystic fibrosis in patients who have a faulty mutation in the CFTR gene in line with NHS England Clinical Commissioning Policy.
Only available from:
<
12/10/2023 11:12:16
(DavidS )
UPD
Ivacaftor updated typo
12/10/2023 11:12:16
(DavidS )
UPD
sitematrix Changed from 0 to
12/10/2023 11:08:53
(DavidS )
UPD
FurtherInformation Changed from
Approved for the treatment of cystic fibrosis in patients who have a faulty mutation in the CFTR gene in line with NHS England Clinical Commissioning Policy.
Only available from:
<
12/10/2023 11:08:53
(DavidS )
UPD
Ivacaftor updated typo
12/10/2023 11:08:53
(DavidS )
UPD
sitematrix Changed from 0 to
12/10/2023 10:56:01
(DavidS )
UPD
FurtherInformation Changed from
Approved for the treatment of cystic fibrosis in patients who have a faulty mutation in the CFTR gene in line with NHS England Clinical Commissioning Policy.
Only available from:
<
12/10/2023 10:56:01
(DavidS )
UPD
Ivacaftor updated
12/10/2023 10:56:01
(DavidS )
UPD
sitematrix Changed from 0 to
12/10/2023 10:55:30
(DavidS )
UPD
FurtherInformation Changed from
Approved for the treatment of cystic fibrosis in patients who have a faulty mutation in the CFTR gene in line with NHS England Clinical Commissioning Policy.
to
Approved for the
12/10/2023 10:55:30
(DavidS )
UPD
Ivacaftor updated
12/10/2023 10:55:30
(DavidS )
LDL
Link Added : Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis : https://www.england.nhs.uk/publication/commissioning-statement-ivacaftor-tezacaftor-ivacaftor-lumacaftor
12/10/2023 10:53:26
(DavidS )
LDL
Link Added : MHRA Drug Safety Update (Feb 2022): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on liver function testing : https://www.gov.uk/drug-safety-update/i
07/07/2023 11:23:24
(ebeavers )
UPD
Ivacaftor b
27/01/2017 10:08:07
(WhitehallJ )
UPD
Ivacaftor b
27/01/2017 10:07:05
(WhitehallJ )
LDL
Link Added : Clinical Commissioning Policy: Ivacaftor for children aged 2-5 years with cystic fibrosis (named mutations) : https://www.england.nhs.uk/wp-content/uploads/2016/12/clin-comm-pol-16049P.pdf
17/01/2017 10:44:19
(LoweryM )
LDL
Link Added : Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis : https://www.england.nhs.uk/wp-content/uploads/2013/04/a01-p-b.pdf
17/01/2017 10:41:01
(LoweryM )
UPD
Ivacaftor B
17/01/2017 10:40:12
(LoweryM )
UPD
Ivacaftor B
17/01/2017 10:39:50
(LoweryM )
UPD
Ivacaftor b
17/01/2017 10:19:30
(LoweryM )